Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20658
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarvouni, E.en
dc.contributor.authorKatritsis, D. G.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T19:09:08Z-
dc.date.available2015-11-24T19:09:08Z-
dc.identifier.issn0735-1097-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20658-
dc.rightsDefault Licence-
dc.subjectAngioplasty, Balloon, Coronary/adverse effects/*mortalityen
dc.subjectAntibodies, Monoclonal/*administration & dosageen
dc.subjectAtherectomy, Coronary/adverse effects/*mortalityen
dc.subjectCoronary Disease/etiologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectImmunoglobulin Fab Fragments/*administration & dosageen
dc.subjectInfusions, Intravenousen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMulticenter Studies as Topicen
dc.subjectMyocardial Infarction/etiologyen
dc.subjectPeptides/*administration & dosageen
dc.subjectPlatelet Aggregation Inhibitors/*administration & dosageen
dc.subjectPlatelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitorsen
dc.subjectPostoperative Hemorrhage/etiologyen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRisken
dc.subjectStents/adverse effectsen
dc.subjectSurvival Analysisen
dc.subjectTyrosine/*administration & dosage/analogs & derivativesen
dc.titleIntravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventionsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12570940-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractOBJECTIVES: We sought to evaluate the impact of intravenous antagonists of the platelet IIb/IIIa receptor on the survival of patients undergoing percutaneous coronary interventions (PCIs). BACKGROUND: Several trials have shown that intravenous antagonists of the platelet glycoprotein (GP) IIb/IIIa receptor reduce the incidence of myocardial infarction (MI) and composite cardiac outcomes (death, MI, or revascularization) in patients undergoing PCI. However, individual studies have not had adequate power to examine differences in mortality. METHODS: We performed a meta-analysis of 19 randomized, placebo-controlled trials (20 comparisons, n = 20,137). Death was the primary outcome. Secondary outcomes included MI, composite cardiac outcomes, and major bleeding. RESULTS: Mortality was significantly reduced at 30 days (risk ratio [RR] 0.69 [95% confidence interval [CI] 0.53 to 0.90]), at six months (RR 0.79 [95% CI 0.64 to 0.97]), and including longer follow-up (RR 0.79 [95% CI 0.66 to 0.94]), with no significant between-study heterogeneity. The relative risk reduction was largely similar in trials of patients with or without acute myocardial infarction (AMI), in trials continuing or discontinuing heparin after the procedure, and in trials using stents or another PCI as the intended primary procedure. Myocardial infarction and composite outcomes were significantly reduced (p < 0.001 for all) at 30 days and six months. Major bleeding was significantly increased only in trials where heparin infusion was continued after the procedure (RR 1.70 [95% CI 1.36 to 2.14]), although there was no excess bleeding when heparin was discontinued (RR 1.02 [95% CI 0.85 to 1.24]). CONCLUSIONS: In patients undergoing PCI, GP IIb/IIIa receptor antagonists confer a significant and sustained decrease (20% to 30%) in the risk of death.en
heal.journalNameJ Am Coll Cardiolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons